Solasia Pharma K.K. provided consolidated earnings guidance for the year ending December 31, 2021. For the period, the company expected revenue to be in the range of JPY 1,600 million to JPY 2,600 million. Operating loss is expected to be in the range of JPY 2,800 million to JPY 1,800 million. Loss is expected to be in the range of JPY 2,800 million to JPY 1,800 million. Basic loss per share is expected to be in the range of JPY 22.83 compared to JPY 14.68.